HCM
Price
$14.28
Change
-$0.09 (-0.63%)
Updated
Oct 22 closing price
Capitalization
2.48B
22 days until earnings call
Intraday BUY SELL Signals
RMTI
Price
$7.06
Change
-$0.02 (-0.28%)
Updated
Oct 22 closing price
Capitalization
28.46M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HCM vs RMTI

HCM vs RMTI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
HCM vs. RMTI commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a StrongBuy and RMTI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for HCM with price predictions
Oct 22, 2026

Momentum Indicator for HCM turns positive, indicating new upward trend

HCM saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 65 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for HCM moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where HCM advanced for three days, in 197 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

HCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 131 of 183 cases where HCM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for HCM turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. HCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.969) is normal, around the industry mean (10.407). HCM has a moderately high P/E Ratio (142.800) as compared to the industry average of (-6.173). Projected Growth (PEG Ratio) (4.030) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (4.268) is also within normal values, averaging (178.797).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for RMTI with price predictions
Oct 22, 2026

RMTI in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 12, 2026

RMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 37 cases where RMTI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where RMTI advanced for three days, in 195 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for RMTI moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 33 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RMTI as a result. In 59 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for RMTI turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

RMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RMTI crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for RMTI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.811) is normal, around the industry mean (10.407). P/E Ratio (-5.348) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.435) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. RMTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
HCM vs RMTI: Fundamental Ratings
HCM
RMTI
OUTLOOK RATING
1..100
8558
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8194
PRICE GROWTH RATING
1..100
4464
P/E GROWTH RATING
1..100
156
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RMTI's Valuation (20) in the Medical Specialties industry is significantly better than the same rating for HCM (90) in the Pharmaceuticals Major industry. This means that RMTI’s stock grew significantly faster than HCM’s over the last 12 months.

RMTI's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that RMTI’s stock grew similarly to HCM’s over the last 12 months.

HCM's SMR Rating (81) in the Pharmaceuticals Major industry is in the same range as RMTI (94) in the Medical Specialties industry. This means that HCM’s stock grew similarly to RMTI’s over the last 12 months.

HCM's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as RMTI (64) in the Medical Specialties industry. This means that HCM’s stock grew similarly to RMTI’s over the last 12 months.

HCM's P/E Growth Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for RMTI (56) in the Medical Specialties industry. This means that HCM’s stock grew somewhat faster than RMTI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HCMRMTI
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 24 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (HCM: $14.37 vs. RMTI: $7.06)
Brand notoriety: HCM and RMTI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HCM: 94% vs. RMTI: 18%
Market capitalization -- HCM: $2.48B vs. RMTI: $28.46M
HCM [@Pharmaceuticals: Generic] is valued at $2.48B. RMTI’s [@Pharmaceuticals: Generic] market capitalization is $28.46M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HCM’s FA Score shows that 1 FA rating(s) are green while RMTI’s FA Score has 1 green FA rating(s).

  • HCM’s FA Score: 1 green, 4 red.
  • RMTI’s FA Score: 1 green, 4 red.
According to our system of comparison, HCM is a better buy in the long-term than RMTI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HCM’s TA Score shows that 5 TA indicator(s) are bullish while RMTI’s TA Score has 3 bullish TA indicator(s).

  • HCM’s TA Score: 5 bullish, 3 bearish.
  • RMTI’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, HCM is a better buy in the short-term than RMTI.

Price Growth

HCM (@Pharmaceuticals: Generic) experienced а +6.60% price change this week, while RMTI (@Pharmaceuticals: Generic) price change was -11.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.

Reported Earning Dates

HCM is expected to report earnings on Nov 13, 2026.

RMTI is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.94% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
HCM
Daily Signal:
Gain/Loss:
RMTI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

HCM and

Correlation & Price change

A.I.dvisor tells us that HCM and ACET have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HCM
1D Price
Change %
HCM100%
-0.63%
ACET - HCM
29%
Poorly correlated
-4.68%
CGC - HCM
27%
Poorly correlated
-1.00%
GELS - HCM
25%
Poorly correlated
-2.23%
SNDL - HCM
25%
Poorly correlated
+0.78%
RMTI - HCM
23%
Poorly correlated
-0.28%
More

RMTI and

Correlation & Price change

A.I.dvisor tells us that RMTI and SNDL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RMTI and SNDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RMTI
1D Price
Change %
RMTI100%
-0.28%
SNDL - RMTI
29%
Poorly correlated
+0.78%
ZSTK - RMTI
24%
Poorly correlated
-5.88%
IRWD - RMTI
22%
Poorly correlated
+0.56%
AMLX - RMTI
22%
Poorly correlated
-1.58%
INCR - RMTI
22%
Poorly correlated
-0.45%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BX118.759.18
+8.38%
Blackstone
ESCA18.890.40
+2.16%
Escalade
RDAC4.72N/A
N/A
Rising Dragon Acquisition Corp.
IRS14.21-0.04
-0.28%
IRSA Inversiones Y Representaciones S.A
CPA134.86-1.28
-0.94%
Copa Holdings SA